Cargando…

Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood

During metastasis, circulating tumor cells migrate away from a primary tumor via the blood circulation to form secondary tumors in distant organs. Mounting evidence from clinical observations indicates that the number of circulating tumor cells (CTCs) in the blood correlates with the progression of...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiahe, Sharkey, Charles C., Huang, Dantong, King, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361771/
https://www.ncbi.nlm.nih.gov/pubmed/25798204
http://dx.doi.org/10.1007/s12195-015-0381-z
_version_ 1782361703576502272
author Li, Jiahe
Sharkey, Charles C.
Huang, Dantong
King, Michael R.
author_facet Li, Jiahe
Sharkey, Charles C.
Huang, Dantong
King, Michael R.
author_sort Li, Jiahe
collection PubMed
description During metastasis, circulating tumor cells migrate away from a primary tumor via the blood circulation to form secondary tumors in distant organs. Mounting evidence from clinical observations indicates that the number of circulating tumor cells (CTCs) in the blood correlates with the progression of solid tumors before and during chemotherapy. Beyond the well-established role of CTCs as a fluid biopsy, however, the field of targeting CTCs for the prevention or reduction of metastases has just emerged. Conventional cancer therapeutics have a relatively short circulation time in the blood which may render the killing of CTCs inefficient due to reduced exposure of CTCs to drugs. Nevertheless, over the past few decades, the development of nanoparticles and nanoformulations to improve the half-life and release profile of drugs in circulation has rejuvenated certain traditional medicines in the emerging field of CTC neutralization. This review focuses on how the principles of nanomedicine may be applied to target CTCs. Moreover, inspired by the interactions between CTCs and host cells in the blood circulation, novel biomimetic approaches for targeted drug delivery are presented.
format Online
Article
Text
id pubmed-4361771
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-43617712015-03-20 Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood Li, Jiahe Sharkey, Charles C. Huang, Dantong King, Michael R. Cell Mol Bioeng Review Paper During metastasis, circulating tumor cells migrate away from a primary tumor via the blood circulation to form secondary tumors in distant organs. Mounting evidence from clinical observations indicates that the number of circulating tumor cells (CTCs) in the blood correlates with the progression of solid tumors before and during chemotherapy. Beyond the well-established role of CTCs as a fluid biopsy, however, the field of targeting CTCs for the prevention or reduction of metastases has just emerged. Conventional cancer therapeutics have a relatively short circulation time in the blood which may render the killing of CTCs inefficient due to reduced exposure of CTCs to drugs. Nevertheless, over the past few decades, the development of nanoparticles and nanoformulations to improve the half-life and release profile of drugs in circulation has rejuvenated certain traditional medicines in the emerging field of CTC neutralization. This review focuses on how the principles of nanomedicine may be applied to target CTCs. Moreover, inspired by the interactions between CTCs and host cells in the blood circulation, novel biomimetic approaches for targeted drug delivery are presented. Springer US 2015-02-24 /pmc/articles/PMC4361771/ /pubmed/25798204 http://dx.doi.org/10.1007/s12195-015-0381-z Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Review Paper
Li, Jiahe
Sharkey, Charles C.
Huang, Dantong
King, Michael R.
Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood
title Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood
title_full Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood
title_fullStr Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood
title_full_unstemmed Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood
title_short Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood
title_sort nanobiotechnology for the therapeutic targeting of cancer cells in blood
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361771/
https://www.ncbi.nlm.nih.gov/pubmed/25798204
http://dx.doi.org/10.1007/s12195-015-0381-z
work_keys_str_mv AT lijiahe nanobiotechnologyforthetherapeutictargetingofcancercellsinblood
AT sharkeycharlesc nanobiotechnologyforthetherapeutictargetingofcancercellsinblood
AT huangdantong nanobiotechnologyforthetherapeutictargetingofcancercellsinblood
AT kingmichaelr nanobiotechnologyforthetherapeutictargetingofcancercellsinblood